Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” fourth quarter 2024 investor letter. A copy ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced a collaboration with Biosero, a developer of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

Becton Dickinson plans to invest more than $30M in 2025 to expand its manufacturing capacity for IV lines at its Utah plant.

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

近日，贝克顿·迪金森公司 (Becton Dickinson & Co) (NYSE: BDX )执行副总裁兼首席ISC官Shan David出售了500股公司普通股。每股售价为240.00美元，总计12万美元。此次出售后，David仍持有公司5,741股股份。

Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals have a strong correlation with market price movements, so we decided to look at ...

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free ...

贝克顿·迪金森公司 (Becton Dickinson & Co.) (NYSE: BDX )执行副总裁兼医疗部门总裁Michael David Garrison最近出售了597股公司普通股。这些股票以平均价格236.51美元售出，交易总额为141,196美元。此次出售后，Garrison直接持有5,544股。